Sugi Predict

Sugi Predict / Compounds / SCHEMBL9956855

SCHEMBL9956855

SCHEMBL9956855

O=C(O)NCC1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ EPHX1 P07099 2/20 0.39
▸ NAMPT P43490 3/20 0.39
▸ EPHX2 P34913 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ MMP1 P03956 1/20 0.37
▸ MMP2 P08253 1/20 0.37
▸ MMP3 P08254 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ BRD4 O60885 1/20 0.36
▸ PDE8B O95263 1/20 0.36
▸ CNR2 P34972 3/20 0.35
▸ CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707639 0.88 CYP2D6 (0.46) CYP2D6TDP1NPC1RAB9ANAMPT
SCHEMBL5314921 0.85 HTR4 (0.48) CYP2D6PDE8B
SCHEMBL217411 0.84 — —
SCHEMBL4396572 0.84 CYP2D6 (0.63) CYP2D6TDP1NPC1RAB9AEPHX1
SCHEMBL4396576 0.84 CYP2D6 (0.63) CYP2D6TDP1NPC1RAB9AEPHX1
Hydrochloric Acid SCHEMBL4316280 0.81 — —
SCHEMBL23148758 0.81 RAB9A (0.39) CYP2D6TDP1NPC1RAB9AEPHX1
SCHEMBL18028783 0.81 TDP1 (0.72) CYP2D6TDP1NPC1RAB9AEPHX1
SCHEMBL18936070 0.81 TDP1 (0.43) CYP2D6TDP1NPC1RAB9AEPHX1
SCHEMBL3394009 0.81 NPC1 (0.43) TDP1NPC1RAB9AEPHX1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4554934-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 — — EP disclosed
WO-2024015503-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 — — WO disclosed
US-11718603-B2 CDK2 inhibitors PFIZER INC. (US) 2023-08-08 — — US disclosed
WO-2023069708-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 — — WO disclosed
EP-3613737-B1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2021-12-29 — — EP disclosed
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR PLEXXIKON INC. 2021-07-01 — — US disclosed
US-11014911-B2 CDK2 inhibitors PFIZER INC. (US) 2021-05-25 — — US disclosed
US-10968213-B2 Cyclopropanamine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-06 — — US disclosed
US-10952999-B2 Inhibitor of cyclin-dependent kinase CDK9 GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2021-03-23 — — US disclosed
US-20200247784-A1 CDK2 INHIBITORS PFIZER INC. (US) 2020-08-06 — — US disclosed
US-10035777-B2 Heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-31 — — US disclosed
US-20180162853-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2018-06-14 — — US disclosed
US-20170217966-A1 PYRAZOLOPYRIMIDINE COMPOUNDS UNIVERSITY HEALTH NETWORK (CA) 2017-08-03 — — US disclosed
US-9573954-B2 Pyrazolopyrimidine compounds UNIVERSITY HEALTH NETWORK (CA) 2017-02-21 — — US disclosed
US-20150299203-A1 PYRAZOLOPYRIMIDINE COMPOUNDS UNIVERSITY HEALTH NETWORK (CA) 2015-10-22 — — US disclosed
EP-2920181-A1 PYRAZOLOPYRIMIDINE COMPOUNDS University Health Network (UHN) (CA) 2015-09-23 — — EP disclosed
WO-2015007613-A1 O-ALKYL TRIAZOLYL CARBAMATES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2015-01-22 — — WO disclosed
WO-2014075168-A1 PYRAZOLOPYRIMIDINE COMPOUNDS UNIVERSITY HEALTH NETWORK (CA) 2014-05-22 — — WO disclosed
EP-2655323-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2013-10-30 — — EP disclosed
WO-2012083953-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO PHARMA A/S (DK) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299203-A1 PYRAZOLOPYRIMIDINE COMPOUNDS CYP3A5, CYP3A7, DPYD CYP2D6 6/4885TDP1 780/4885NPC1 487/4885
US-20210198239-A1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR ENTPD5, ADORA2A, ENTPD1 CYP2D6 982/4885TDP1 570/4885NPC1 1512/4885
US-20180162853-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF KDM1A, KDM1B, KDM2A CYP2D6 3821/4885TDP1 227/4885NPC1 2011/4885
US-20200247784-A1 CDK2 INHIBITORS CDK2, CDK1, CCNI CYP2D6 1144/4885TDP1 1626/4885NPC1 3325/4885
US-10952999-B2 Inhibitor of cyclin-dependent kinase CDK9 CDK9, CDK19, CDK1 CYP2D6 2950/4885TDP1 894/4885NPC1 3572/4885
US-20170217966-A1 PYRAZOLOPYRIMIDINE COMPOUNDS CYP3A5, CYP3A7, DPYD CYP2D6 9/4885TDP1 1380/4885NPC1 710/4885
US-11718603-B2 CDK2 inhibitors CDK2, CDK1, CCNI CYP2D6 1144/4885TDP1 1626/4885NPC1 3325/4885
US-10968213-B2 Cyclopropanamine compound and use thereof KDM1A, KDM1B, KDM2A CYP2D6 3821/4885TDP1 227/4885NPC1 2011/4885
US-10035777-B2 Heterocyclic kinase inhibitors AAK1, NCK1, DAPK2 CYP2D6 4664/4885TDP1 1759/4885NPC1 3364/4885
US-11014911-B2 CDK2 inhibitors CDK2, CDK1, CCNI CYP2D6 1144/4885TDP1 1626/4885NPC1 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.